Infectious complications associated with immune and targeted anti-cancer therapies: a retrospective study of the FDA adverse events reporting system (FAERS)
- 1 February 2025
- journal article
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 25 (7) , 1399-1406
Abstract
Immune and targeted anti-cancer therapies are associated with an increased risk of infectious complications. The objectives of the present study were to evaluate the infectious complications associated with immune and targeted anti-cancer drugs. This was a retrospective for immune and targeted anti-cancer drugs submitted to the FDA Adverse Event Reporting System (FAERS) from 1996 to 20 March 2024. The primary outcome was the rate of infectious disease events, and the secondary outcomes were the incidence of febrile neutropenia (FN), all-cause mortality, and the top 10 infections in each class. Our study included 14 drug classes comprising 44 drugs. The incidence of infectious complications was 14.31% (110,671/773,130). The highest incidence rate was reported with IL-6 inhibitors (30.89%), the highest incidence of FN was reported with Histone deacetylase inhibitors (8.43%), and the highest all-cause mortality was reported with BCR-ABL tyrosine kinase inhibitors (17.17%). Immune and targeted anti-cancer therapies vary in the incidence of infectious complications. Pirtobrutinib, copanlisib, sirolimus, vorinostat, and tocilizumab were associated with high infectious complications (>30%) that warrant emphasis in the clinical guidelines. Thus, clinicians should vigilantly monitor patients undergoing immune and targeted therapies for infectious complications and use antimicrobial prophylaxes when indicated.Keywords
Funding Information
- Scientific Research Deanship at the University of Ha’il – Saudi Arabia
This publication has 25 references indexed in Scilit:
- Infectious complications of immune checkpoint inhibitors in solid organ malignanciesCancer Medicine, 2021
- Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013–2020International Journal of Clinical Pharmacy, 2021
- Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real‐world studyCancer Medicine, 2021
- m-TOR inhibitors and risk of Pneumocystis pneumonia after solid organ transplantation: a systematic review and meta-analysisEuropean Journal of Clinical Pharmacology, 2019
- Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell CarcinomaJAMA Network Open, 2019
- Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literatureInfection, 2018
- Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy erasCancer Medicine, 2015
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia VeraNew England Journal of Medicine, 2015
- The Effect of Targeted Therapy on Overall Survival in Advanced Renal Cancer: A Study of the National Surveillance Epidemiology and End Results Registry DatabaseClinical Genitourinary Cancer, 2014
- Large-sample multiple comparisons.Psychological Bulletin, 1966